Search hospitals > Texas > San Antonio
South Texas Accelerated Research Therapeutics
Claim this profileSan Antonio, Texas 78229
Global Leader in Solid Tumors
Global Leader in Tumors
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast Cancer
233 reported clinical trials
7 medical researchers
Summary
South Texas Accelerated Research Therapeutics is a medical facility located in San Antonio, Texas. This center is recognized for care of Solid Tumors, Tumors, Cancer, Non-Small Cell Lung Cancer, Breast Cancer and other specialties. South Texas Accelerated Research Therapeutics is involved with conducting 233 clinical trials across 163 conditions. There are 7 research doctors associated with this hospital, such as Amita Patnaik, MD, Drew W Rasco, MD, Kyriakos Papadopoulos, MD, and Kyri Papadopoulos, MD.Area of expertise
1Solid Tumors
Global LeaderStage IV
Stage III
PD-L1 positive
2Tumors
Global LeaderStage IV
Stage III
KRAS positive
Top PIs
Amita Patnaik, MDSouth Texas Accelerated Research Therapeutics4 years of reported clinical research
Expert in Tumors
Studies Solid Tumors
17 reported clinical trials
24 drugs studied
Drew W Rasco, MDSTART South Texas Accelerated Research Therapeutics7 years of reported clinical research
Expert in Tumors
Studies Solid Tumors
19 reported clinical trials
32 drugs studied
Kyriakos Papadopoulos, MDSouth Texas Accelerated Research Therapeutics2 years of reported clinical research
Studies Solid Tumors
Studies Tumors
7 reported clinical trials
10 drugs studied
Kyri Papadopoulos, MDSouth Texas Accelerated Research Therapeutics6 years of reported clinical research
Studies Oral Squamous Cell Carcinoma
Studies Cancer
2 reported clinical trials
2 drugs studied
Clinical Trials running at South Texas Accelerated Research Therapeutics
Solid Tumors
Tumors
Cancer
Non-Small Cell Lung Cancer
Breast Cancer
Esophageal Cancer
Pancreatic Cancer
Squamous Cell Carcinoma
Prostate Cancer
Colorectal Cancer
Pembrolizumab
for Advanced Cancers
Recruiting2 awards Phase 34 criteria
PM54
for Solid Tumors
The first part of the study (phase Ia - dose escalation) will evaluate the safety and tolerability and identify the dose-limiting toxicities (DLTs) of PM54. The second part of the study (phase Ib - expansion) will be to evaluate the antitumor activity of PM54 in terms of clinical benefit (response or stable disease [SD] ≥4 months associated with tumor shrinkage), according to the RECIST v.1.1 and/or serum markers as appropriate, in patients with selected advanced solid tumors.
Recruiting1 award Phase 1
ABBV-303 + Budigalimab
for Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-303 as a monotherapy and in combination with budigalimab, (ABBV-181). ABBV-303 is an investigational drug being developed for the treatment of solid tumors. There are multiple treatment arms in this study. Participants will either receive ABBV-303 as a single agent or in combination with budigalimab (another investigational drug) at different doses. Approximately 181 adult participants will be enrolled in the study across sites worldwide. In Part A, ABBV-303 will be intravenously (IV) infused in escalating doses as a monotherapy in participants with relapsed (R)/refractory (R) solid tumors, R/R non-small cell lung cancer (NSCLC), R/R renal cell carcinoma (RCC), R/R head and neck squamous cell carcinoma (HNSCC), or R/R tissue agnostic participants with mesenchymal epithelial transition. In Part B, ABBV-303 in combination with budigalimab will be IV infused in participants with R/R solid tumors or NSCLC. The estimated duration of the study is up to 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Recruiting1 award Phase 14 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at South Texas Accelerated Research Therapeutics?
South Texas Accelerated Research Therapeutics is a medical facility located in San Antonio, Texas. This center is recognized for care of Solid Tumors, Tumors, Cancer, Non-Small Cell Lung Cancer, Breast Cancer and other specialties. South Texas Accelerated Research Therapeutics is involved with conducting 233 clinical trials across 163 conditions. There are 7 research doctors associated with this hospital, such as Amita Patnaik, MD, Drew W Rasco, MD, Kyriakos Papadopoulos, MD, and Kyri Papadopoulos, MD.